Payment overview · 2025
General Payments
$282.23
15 reported records · 11 companies
Healthcare provider profile · identity verified
Krystal Barnett
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MACON, MO · NPI 1437552213
Verified facts
What the public records show
CMS Open Payments records show Krystal Barnett received $282.23 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.74 | 20.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.43 | 14.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.30 | 10.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $24.44 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.16 | 8.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.93 | 7.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.68 | 7.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.06 | 6.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.40 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 5.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.45 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $282.23 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.74 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 259 | 48 |
| Omeprazole | Omeprazole | 241 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 40 |
| Potassium Chloride | Potassium Chloride | 141 | 35 |
| Lisinopril | Lisinopril | 137 | 45 |
| Gabapentin | Gabapentin | 120 | 28 |
| Losartan Potassium | Losartan Potassium | 116 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 23 |
| Sertraline Hcl | Sertraline Hcl | 95 | 23 |
| Furosemide | Furosemide | 93 | 24 |
| Celecoxib | Celecoxib | 85 | 13 |
| Metformin Hcl | Metformin Hcl | 84 | 26 |
| Carvedilol | Carvedilol | 83 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 21 |
| Trazodone Hcl | Trazodone Hcl | 78 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 18 |
| Buspirone Hcl | Buspirone Hcl | 76 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 15 |
| Simvastatin | Simvastatin | 70 | 18 |
| Famotidine | Famotidine | 57 | 19 |
| Bupropion Xl | Bupropion Hcl | 55 | 13 |
| Metformin Hcl Er | Metformin Hcl | 55 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 13 |
| Atenolol | Atenolol | 50 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 14 |
| Glimepiride | Glimepiride | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Meloxicam | Meloxicam | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 17 |
| Digoxin | Digoxin | 41 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Prednisone | Prednisone | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Topiramate | Topiramate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 13 |
| Azithromycin | Azithromycin | 19 | 17 |
| Estradiol | Estradiol | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Eliquis | Apixaban | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Misoprostol | Misoprostol | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $282.23 · 15 records | Amgen Inc. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, EVENITY, JOURNAVX, Jornay PM, Kerendia, Ozempic, PREVNAR 20, REXULTI, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error